MBX Biosciences, Inc. (MBX)
MBXNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$56.33
+2.27 (+4.20%) today
At the close, Nov 10, 4:00 PM ET. After hours $56.33 –
- Market cap
- $2.71bn
- P/E
- –
- EPS, last 4 quarters
- $-3.07
- Dividend yield
- –
- Day range
- $51.52 to $58.12
- 52-week range
- $23.07 to $72.64
- Average volume
- 527.0k
- Previous close
- $54.06
Analysts
7 coveringBuy6 buy, 1 hold, 0 sell
Targets a year out average $102.50, +82.0% from here
Earnings
next estimate $-0.8700Next report
Dec 2025
+23.4%
Mar 2026
+17.7%
Jun 2026
-14.7%
Sep 2026
-61.3%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$23.93m | -$25.80m | -$27.27m | -$40.93m |
| Net income | -$21.62m | -$22.06m | -$23.52m | -$37.09m |
News
8 latest- MBX Biosciences Advances Canvuparatide Into Phase 3 Development For Hypoparathyroidism RTTNews · Aug 27, 2026
- 6 Biotech Stocks That Delivered Stunning Gains: INBX +700%, PVLA +500%, MBX +300%, ABSI +200% & More RTTNews · Jun 24, 2026
- Top Biotech Gainers: VRXA Begins A New Chapter, ADIL Opens Wallet, PGEN, PCSA On Watch... RTTNews · Jun 11, 2026
- Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 RunThe Motley Fool · May 27, 2026
- MBX Biosciences (MBX) Price Target Increased by 11.23% to 69.55Fintel · May 13, 2026
- MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline PushMarketBeat · May 11, 2026
- 3 Overlooked Stocks Set to Soar in 2026The Motley Fool · May 5, 2026
- Aaron Wealth Makes a Big Bet on MBX Biosciences With a 1.1 Million Share PurchaseThe Motley Fool · Apr 22, 2026
The company
MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company's pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism in Phase 3; and an obesity portfolio that includes MBX 4291 in Phase 1, and MBX 5765 and MBX 6180 in preclinical development, as well as additional discovery candidates. The Company is based in Carmel, Indiana and Burlington, Massachusetts.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- mbxbio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.